Document Detail


Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?
MedLine Citation:
PMID:  19546178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model. Japanese white rabbits (n=32) were randomly separated into four equal groups. 45 min after introducing autologous fibrin clot, Group U received urokinase and heparin; Group E received urokinase and heparin plus edaravone; Group A received urokinase and heparin plus asialoerythropoietin; and Group EA received urokinase, heparin and edaravone plus asialoerythropoietin via a catheter. The intestines were removed 6 h later and intestinal mucosal damage was scored using the Park's injury score. Survival time was assessed. Average mucosal injury was 5.78+/-1.52 (Group U), 2.88+/-0.72 (Group E), 1.90+/-1.23 (Group A) and 1.18+/-1.25 (Group EA). The degree of mucosal injury was significantly lower in Group EA than in Groups U and E (p<0.05). Conversely, there was no significant difference between Group A and Group EA, or between Group A and Group E. The survival times were 31.50+/-13.30 h (Group U), 51.00+/-24.74 h (Group E), 48.00+/-16.97 h (Group A) and 82+/-51.07 h (Group EA); the difference among the four groups was not significant. In conclusion, the concomitant administration of asialoerythropoietin and edaravone reduced mucosal membrane injury significantly compared with edaravone alone. However, to improve the survival of ASMAT rabbit models, the delivery of an appropriate dose of asialoerythropoietin is required, together with the development of methods to assess peripheral recanalisation.
Authors:
A Sonoda; N Nitta; A Seko; S Ohta; S Takemura; T Sugimoto; T Uzu; Y Yokomaku; M Takahashi; A Kashiwagi; K Murata
Related Documents :
9305248 - Internal jugular vein thrombosis after functional and selective neck dissection.
1657248 - Identification of risk factors for bleeding during treatment of acute venous thromboemb...
8633448 - Accuracy of sonography in the evaluation of calf deep vein thrombosis in both postopera...
22531398 - Nipple-sparing mastectomy: technical aspects and aesthetic outcomes.
22547348 - Impact on quality of life after pancreatoduodenectomy: a prospective study comparing pr...
24296538 - Impact of anesthesia on mortality during endovascular clot removal for acute ischemic s...
Publication Detail:
Type:  Journal Article     Date:  2009-06-22
Journal Detail:
Title:  The British journal of radiology     Volume:  83     ISSN:  1748-880X     ISO Abbreviation:  Br J Radiol     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-08     Completed Date:  2010-05-18     Revised Date:  2013-02-19    
Medline Journal Info:
Nlm Unique ID:  0373125     Medline TA:  Br J Radiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  129-32     Citation Subset:  AIM; IM    
Affiliation:
Department of Radiology, Shiga University of Medical Science, Shiga, Japan. akinaga@belle.shiga-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipyrine / administration & dosage,  analogs & derivatives*,  pharmacology
Asialoglycoproteins / administration & dosage*,  pharmacology
Catheterization
Disease Models, Animal
Drug Combinations
Erythropoietin / administration & dosage,  analogs & derivatives*,  pharmacology
Fibrin
Fibrinolytic Agents / therapeutic use
Free Radical Scavengers / administration & dosage*,  pharmacology
Heparin / therapeutic use
Injections, Intra-Arterial
Intestinal Mucosa / pathology
Mesenteric Artery, Superior
Mesenteric Vascular Occlusion / complications*,  drug therapy,  mortality
Rabbits
Random Allocation
Reperfusion Injury / etiology,  pathology,  prevention & control*
Survival Rate
Thromboembolism / complications*,  drug therapy,  mortality
Urokinase-Type Plasminogen Activator / therapeutic use
Chemical
Reg. No./Substance:
0/Asialoglycoproteins; 0/Drug Combinations; 0/Fibrinolytic Agents; 0/Free Radical Scavengers; 0/asialoerythropoietin; 11096-26-7/Erythropoietin; 60-80-0/Antipyrine; 9001-31-4/Fibrin; 9005-49-6/Heparin; EC 3.4.21.73/Urokinase-Type Plasminogen Activator; S798V6YJRP/phenylmethylpyrazolone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enhancement pattern of the normal facial nerve at 3.0 T temporal MRI.
Next Document:  Incidental breast lesions detected on CT: what is their significance?